COMPUTED DESCRIPTORS
| Molecular Weight | 1595.6 g/mol |
|---|---|
| Hydrogen Bond Donor Count | 14 |
| Hydrogen Bond Acceptor Count | 25 |
| Rotatable Bond Count | 23 |
| Exact Mass | 1594.53583 g/mol |
| Monoisotopic Mass | 1594.53583 g/mol |
| Topological Polar Surface Area | 540 Ų |
| Heavy Atom Count | 100 |
| Formal Charge | 0 |
| Complexity | 2600 |
| Isotope Atom Count | 1 |
| Defined Atom Stereocenter Count | 10 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 2 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Lutetium Lu 177-Edotreotide is a radioconjugate consisting of the somatostatin analogue edotreotide labeled with lutetium Lu 177 with potential antineoplastic activities. Lutetium Lu 177-edotreotide binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide (Tyr3-octreotide or TOC) and chelated by the bifunctional, macrocyclic chelating agent dodecanetetraacetic acid (DOTA).